86937-80-6

Usage

Uses

Used in Organic Synthesis:
2-TERT-BUTOXYCARBONYLAMINO-3-(4-NITRO-PHENYL)-PROPIONIC ACID is used as a key intermediate in organic synthesis for the creation of a variety of complex organic molecules. Its unique structure allows it to be a versatile component in the formation of new compounds with specific properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-TERT-BUTOXYCARBONYLAMINO-3-(4-NITRO-PHENYL)-PROPIONIC ACID is used as a building block for the synthesis of pharmaceuticals. Its incorporation into drug molecules can potentially lead to the development of new treatments and therapies.
Used in the Development of New Materials:
2-TERT-BUTOXYCARBONYLAMINO-3-(4-NITRO-PHENYL)-PROPIONIC ACID may also have applications in material science, where it could be used in the development of new materials with unique properties. Its structural features make it a candidate for further exploration in this area.
Used as a Reagent in Chemical Reactions:
2-TERT-BUTOXYCARBONYLAMINO-3-(4-NITRO-PHENYL)-PROPIONIC ACID can be employed as a reagent in various chemical reactions, facilitating specific transformations and processes that are important in the synthesis of target molecules.
While the exact applications and uses of 2-TERT-BUTOXYCARBONYLAMINO-3-(4-NITRO-PHENYL)-PROPIONIC ACID are still being explored, its presence in the fields of organic synthesis, medicinal chemistry, material development, and as a reagent in chemical reactions highlights its potential as a valuable compound in scientific research and industrial applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1991-83-9 4-nitrophenylalanine 
• 63-91-2 L-phenylalanine 
• 123-91-1 1,4-dioxane 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 56613-61-7 (R)-4-nitro-phenylalanine 
• 673-06-3 D-(R)-phenylalanine 

Downstream Products

• 66163-66-4 2-tert-Butoxycarbonylamino-3-(4-nitro-phenyl)-propionic acid 4-nitro-phenyl ester 
• 55533-24-9 L-N-tert-butoxycarbonyl-p-aminophenylalanine 
• 81085-48-5 N-alpha-[3-(N-alpha-tert-butyloxycarbonyl-4-nitrophenylalanylthio)-2-trifluoromethylpropanoyl]-L-proline 
• 86937-81-7 ethyl 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[N-tert-butoxycarbonyl-β-(4-nitrophenyl)-D,L-alanylamino]-β-D-ribofuranuronate 
• 220387-46-2 ethyl 5-(N-t-butoxycarbonyl-L-4-nitrophenylalanyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-acetate 
• 34276-53-4 ethyl (S)-2-amino-3-(4-nitrophenyl)propionate 
• 55533-24-9 N-Boc-4-aminophenylalanine 
• 199336-08-8 {(1R,2R)-2-[(R)-2-tert-Butoxycarbonylamino-3-(4-nitro-phenyl)-propionylamino]-cyclohexyl}-carbamic acid benzyl ester 
• 199336-09-9 {(1S,2S)-2-[(R)-2-tert-Butoxycarbonylamino-3-(4-nitro-phenyl)-propionylamino]-cyclohexyl}-carbamic acid tert-butyl ester 
• 199336-06-6 {(1S,2S)-2-[(R)-2-tert-Butoxycarbonylamino-3-(4-nitro-phenyl)-propionylamino]-cyclohexyl}-carbamic acid benzyl ester 
• 122566-51-2 N^α-t-BOC-trans-4-aminocyclohexyl-D-alanine 
• 132695-92-2 N^α-t-BOC-cis-4-aminocyclohexyl-D-alanine 
• 746674-76-0 Boc-D-Phe(4-NO₂)-NMe 
• 1373883-34-1 (R,E)-N-(3-(4-((3,5-bis(trifluoromethyl)phenyl)diazenyl)phenyl)-1-((2-hydroxyphenyl)amino)-1-oxopropan-2-yl)-2-hydroxybenzamide 

Relevant academic research and scientific papers

Cyclic side-chain-linked opioid analogs utilizing cis- and trans-4-aminocyclohexyl-d-alanine

Cyclization of linear sequences is a well recognized tool in opioid peptide chemistry for generating analogs with improved bioactivities. Cyclization can be achieved through various bridging bonds between peptide ends or side-chains. In our earlier paper we have reported the synthesis and biological activity of a cyclic peptide, Tyr-c[d-Lys-Phe-Phe-Asp]NH2 (1), which can be viewed as an analog of endomorphin-2 (EM-2, Tyr-Pro-Phe-Phe-NH2). Cyclization was achieved through an amide bond between side-chains of d-Lys and Asp residues. Here, to increase rigidity of the cyclic structure, we replaced d-Lys with cis- or trans-4-aminocyclohexyl-d-alanine (d-ACAla). Two sets of analogs incorporating either Tyr or Dmt (2′,6′-dimethyltyrosine) residues in position 1 were synthesized. In the binding studies the analog incorporating Dmt and trans-d-ACAla showed high affinity for both, μ- and δ-opioid receptors (MOR and DOR, respectively) and moderate affinity for the κ-opioid receptor (KOR), while analog with Dmt and cis-d-ACAla was exceptionally MOR-selective. Conformational analyses by NMR and molecular docking studies have been performed to investigate the molecular structural features responsible for the noteworthy MOR selectivity.

Synthesis and?antiproliferative activities of?indolin-2-one?derivatives bearing amino acid moieties

A convenient synthesis of indolin-2-ones substituted in the 3 position by an aminomethylene group bearing different amino acid moieties is described. Their antiproliferative activities were evaluated toward a panel of human solid tumor cell lines (PC 3, DLD-1, MCF-7, M4 Beu, A549, PA 1) and healthy cell lines (a murine fibroblast L929 and a human fibroblast primary culture).

Aniline derivatives possessing an inhibitory effect of nitric oxide synthase

Compounds represented by the general formula (1): ? (where R1is SR6or NR7R8, where R6is typically an alkyl group having 1-6 carbon atoms, R7is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2and R3are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3and Y4which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof. The compounds possess a potent nitric oxide synthase inhibiting activity and are useful as therapeutics of cerebrovascular diseases.

Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p- nitrobenzyl)-trans-CyDTPA

Distinct differences in in vivo stability of the two diastereomeric C- Functionalized CyDTPA chelating agents, (CHX-A DTPA and CHX-B DTPA, both racemates), as recently reported prompted further investigation as to why differences in configuration produced striking effects on the in vivo stability of their yttrium complexes. To this end, the four individual component stereoisomers of CHX-A and CHX-B were synthesized and ability to bind yttrium was investigated both in vitro and in vivo.

Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. 2

Tyrosine-specific protein kinases that transfer the terminal phosphate from ATP to protein acceptors are associated with certain transforming viruses and cell surface growth factor receptors. Here we describe the synthesis and testing of potential multisubstrate inhibitors of this class of enzymes. The inhibitors were prepared by covalent attachment of the terminal phosphate of ATP or its tetraphosphate analogue to tyrosine mimics. Testing against p60(v-abl), the tyrosine kinase from the Abelson murine leukemia virus, showed that the series of inhibitors was moderately potent (IV50 values as low as 13 μM). However, structural modification of the tyrosine mimic, including replacement with a serine-like moiety, had little effect on potency. It is therefore concluded that the ATP moiety is largely responsible for binding and that the enzyme requires additional structural features for recognition of the tyrosine-containing substrate.